AGENUS INC (AGEN)
US00847G7051 - Common Stock
Taking everything into account, AGEN scores 2 out of 10 in our fundamental rating. AGEN was compared to 602 industry peers in the Biotechnology industry. AGEN may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, AGEN is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year AGEN has reported negative net income.
In the past year AGEN has reported a negative cash flow from operations.
In the past 5 years AGEN always reported negative net income.
AGEN had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of AGEN (-80.72%) is worse than 73.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -80.72% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-47.62%
ROA(5y)-65.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AGEN has a better Gross Margin (89.49%) than 91.14% of its industry peers.
The Profit Margin and Operating Margin are not available for AGEN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 89.49% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
AGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AGEN has been increased compared to 1 year ago.
The number of shares outstanding for AGEN has been increased compared to 5 years ago.
AGEN has a worse debt/assets ratio than last year.
2.2 Solvency
AGEN has an Altman-Z score of -9.68. This is a bad value and indicates that AGEN is not financially healthy and even has some risk of bankruptcy.
AGEN has a Altman-Z score of -9.68. This is in the lower half of the industry: AGEN underperforms 78.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.68 |
ROIC/WACCN/A
WACC10.92%
2.3 Liquidity
A Current Ratio of 0.63 indicates that AGEN may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.63, AGEN is doing worse than 94.15% of the companies in the same industry.
A Quick Ratio of 0.63 indicates that AGEN may have some problems paying its short term obligations.
The Quick ratio of AGEN (0.63) is worse than 93.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.63 | ||
| Quick Ratio | 0.63 |
3. Growth
3.1 Past
The earnings per share for AGEN have decreased by -1.23% in the last year.
Looking at the last year, AGEN shows a quite strong growth in Revenue. The Revenue has grown by 12.24% in the last year.
Measured over the past years, AGEN shows a quite strong growth in Revenue. The Revenue has been growing by 17.97% on average per year.
EPS 1Y (TTM)-1.23%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q15.79%
Revenue 1Y (TTM)12.24%
Revenue growth 3Y-13.23%
Revenue growth 5Y17.97%
Revenue growth Q2Q6.58%
3.2 Future
Based on estimates for the next years, AGEN will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.67% on average per year.
The Revenue is expected to grow by 35.72% on average over the next years. This is a very strong growth
EPS Next Y1.87%
EPS Next 2Y5.31%
EPS Next 3Y6.63%
EPS Next 5Y10.67%
Revenue Next Year13.32%
Revenue Next 2Y12.68%
Revenue Next 3Y15%
Revenue Next 5Y35.72%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AGEN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AGEN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.31%
EPS Next 3Y6.63%
5. Dividend
5.1 Amount
No dividends for AGEN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AGENUS INC
NASDAQ:AGEN (11/28/2023, 7:00:00 PM)
Premarket: 0.7473 +0.05 (+6.76%)0.7
+0.04 (+6.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2023-11-07/bmo
Earnings (Next)03-12 2024-03-12/amc
Inst Owners54.11%
Inst Owner Change-2.87%
Ins Owners5.15%
Ins Owner Change0.44%
Market Cap265.70M
Analysts87.27
Price Target7.65 (992.86%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.72%
Min EPS beat(2)1.14%
Max EPS beat(2)18.3%
EPS beat(4)2
Avg EPS beat(4)2.24%
Min EPS beat(4)-7.77%
Max EPS beat(4)18.3%
Revenue beat(2)1
Avg Revenue beat(2)0.37%
Min Revenue beat(2)-2.08%
Max Revenue beat(2)2.82%
Revenue beat(4)2
Avg Revenue beat(4)13.66%
Min Revenue beat(4)-2.28%
Max Revenue beat(4)56.2%
PT rev (1m)0%
PT rev (3m)-2.09%
EPS NQ rev (1m)60.26%
EPS NQ rev (3m)66.79%
EPS NY rev (1m)0%
EPS NY rev (3m)3.8%
Revenue NQ rev (1m)69.05%
Revenue NQ rev (3m)80.48%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.15%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.63 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.82
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)-0.67
FCFYN/A
OCF(TTM)-0.61
OCFYN/A
SpS0.27
BVpS-0.34
TBVpS-0.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -80.72% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 89.49% | ||
| FCFM | N/A |
ROA(3y)-47.62%
ROA(5y)-65.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 234.14% | ||
| Cap/Sales | 23.86% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.63 | ||
| Quick Ratio | 0.63 | ||
| Altman-Z | -9.68 |
F-Score2
WACC10.92%
ROIC/WACCN/A
Cap/Depr(3y)436.57%
Cap/Depr(5y)287.39%
Cap/Sales(3y)23.17%
Cap/Sales(5y)16.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y (TTM)-1.23%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q15.79%
EPS Next Y1.87%
EPS Next 2Y5.31%
EPS Next 3Y6.63%
EPS Next 5Y10.67%
Revenue 1Y (TTM)12.24%
Revenue growth 3Y-13.23%
Revenue growth 5Y17.97%
Revenue growth Q2Q6.58%
Revenue Next Year13.32%
Revenue Next 2Y12.68%
Revenue Next 3Y15%
Revenue Next 5Y35.72%
EBIT growth 1Y-19.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.02%
EBIT Next 3Y5.36%
EBIT Next 5Y-0.7%
FCF growth 1Y-804.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9071.83%
OCF growth 3YN/A
OCF growth 5YN/A